India has approved its first dengue vaccine, QDENGA, after the DCGI granted market authorization. The vaccine is expected to strengthen dengue prevention and reduce severe infections across the country.
New Delhi: India has taken a major step in the fight against dengue after the Drug Controller General of India (DCGI) granted market authorization to QDENGA, the country’s first approved dengue vaccine. The approval is expected to strengthen India’s efforts to reduce dengue-related hospitalizations and deaths, particularly during the monsoon season when infections typically surge.
Developed by global pharmaceutical company Takeda, QDENGA is designed to provide protection against all four dengue virus serotypes. The vaccine has already been approved and introduced in several countries, and its entry into India marks a significant milestone in the country’s public health strategy against mosquito-borne diseases.
Health experts believe the vaccine could help lower the burden of severe dengue cases, especially in regions that witness recurring outbreaks every year. However, vaccination will complement—not replace—existing preventive measures such as mosquito control, eliminating stagnant water, and public awareness campaigns.
The approval comes as India continues to report seasonal spikes in dengue infections across multiple states. Authorities are expected to issue detailed guidelines regarding the vaccine’s rollout, eligibility criteria, pricing, and availability in the coming weeks.
Medical professionals have welcomed the decision, calling it an important breakthrough in dengue prevention. Public health officials say widespread immunization, along with improved sanitation and vector control, could significantly reduce the impact of the disease in the years ahead.
About the Author
